Among chronic diseases, allergy is documented as the fifth leading group affecting 50 million Americans.
It’s prime allergy season: Here’s a primer on what to advise patients with an itch to ditch.
A look at the science behind the development of lifi tegrast, and where it fi ts into the therapeutic puzzle.
Cutting-edge progress also continues in retina, cornea, dry eye, gene-based science
Retina specialists are finding that apps are not just for music and games anymore.
A new understanding of ribonucleic acid’s activity in cells may lead to breakthroughs in ophthalmic treatment.
A rundown of the most interesting research in a variety of subspecialties presented at this year’s ARVO meeting.
Section Editor Ryan Bouchard interviews John Berdahl, MD.
Ocular Therapeutix™ Begins Enrollment in Phase 3 Clinical Trial for DEXTENZA™ for the Treatment of A
Phase 3 Allergy Program Establishes Clinical Indication Expansion Strategy of DEXTENZA™
The placid ocular surface is actually teeming with life that might hold the secret to treating ophthalmic disease.